Functional Coexpression of HSV-1 Thymidine Kinase and Green Fluorescent Protein: Implications for Noninvasive Imaging of Transgene Expression

Neoplasia

Volumn 1, Issue 2, 1999, Pages 154-161

  Jacobs, Andreas ^a,c   Dubrovin, Michael ^b   Hewett, Jeff ^a   Sena Esteves, Miguel ^a   Tan, Cui Wen ^b   Slack, Mark ^b,c   Sadelain, Michele ^b   Breakefield, Xandra O ^a   Tjuvajev, Juri G ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cancer gene therapy; FIAU; Fusion genes; Ganciclovir; Imaging; Thymidine kinase

Indexed keywords

ANTIVIRUS AGENT; COMPLEMENTARY DNA; DRUG DERIVATIVE; FIALURIDINE; GANCICLOVIR; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; PHOTOPROTEIN; THYMIDINE KINASE; URACIL ARABINOSIDE;

ANIMAL; ARTICLE; CELL CULTURE; CELL SEPARATION; DOSE RESPONSE; ENZYMOLOGY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE THERAPY; GENETIC TRANSDUCTION; GENETICS; HERPES SIMPLEX VIRUS 1; METABOLISM; METHODOLOGY; MOLECULAR CLONING; PROMOTER REGION; RAT; RETROVIRUS; TRANSGENE; WESTERN BLOTTING;

ANIMALS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; BLOTTING, WESTERN; CELL SEPARATION; CLONING, MOLECULAR; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GANCICLOVIR; GENE THERAPY; GREEN FLUORESCENT PROTEINS; HERPESVIRUS 1, HUMAN; LUMINESCENT PROTEINS; MICROSCOPY, FLUORESCENCE; PROMOTER REGIONS (GENETICS); RATS; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; THYMIDINE KINASE; TRANSDUCTION, GENETIC; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 0033139768     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900007     Document Type: Article

References (54)

1. Moolten FL (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46, 5276-5281.
2. Ezzeddine ZD, Martuza RL, Platika D, Short MP, Malick A, Choi B, and Breakefield XO (1991). Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biologist 3, 608-614.
3. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, and Blaese RM (1992). In vivo gene transfer with retroviral vector-producing cells for treatment of experimental brain tumors. Science 256, 1550-1552.
4. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D, Blaese RM, and Oldfield EH (1997). Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3, 1354-1361.
5. Paillard F (1998). Suicide genes against brain tumors. Commentary. Hum Gene Ther 9, 3-4.
6. Wei MX, Tamiya T, Chase M, Boviatsis EJ, Chang TK, Kowall NW, Hochberg FH, Waxman DJ, Breakefield XO, and Chiocca EA (1994). Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 5, 969-978.
7. Sandig V, Brand K, Herwig S, Lukas J, Bartek J, and Strauss M (1997). Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 3, 313-319.
8. Oku T, Tjuvajev JG, Miyagawa T, Sasajima T, Joshi A, Joshi R, Finn R, Claffey KP, and Blasberg RG (1998). Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res 58, 4185-4192.
9. Tjuvajev J, Gansbacher B, Desai R, Bettie B, Kaplitt M, Matei C, Koutcher J, Gilboa E, and Blasberg R (1995). RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-γ. Cancer Res 55, 1902-1910.
10. Mineta T, Rabkin SD, and Martuza RL (1994). Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 54, 3963-3966.
11. Mineta T, Rabkin SD, Yazaki T, Hunter WD, and Martuza RL (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1, 938-943.
12. Yazaki T, Manz HJ, Rabkin SD, and Martuza RL (1995). Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 55, 4752-4756.
13. Miyatake S, Martuza RL, and Rabkin SD (1997). Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther 4, 222-228.
14. Kaplitt M, Tjuvajev J, Leib D, Berk J, Pettigrew K, Posner J, Pfaff D, Rabkin S, and Blasberg R (1994). Mutant herpes simplex virus induced regression of tumors in immunocompetent rats. J Neuro Oncol 19, 137-147.
15. Boviatsis EJ, Scharf JM, Chase M, Harrington K, Kowall NW, Breakefield XO, and Chiocca EA (1994). Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther 1, 323-331.
16. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, and McCormick F (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
17. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, and Kirn DH (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3, 639-645.
18. Kramm CM, Sena-Esteves M, Barnett FH, Rainov NG, Schuback DE, Yu JS, Pechan PA, Paulus W, Chiocca EA, and Breakefield XO (1995). Gene therapy for brain tumors. Brain Pathol 4, 345-381.
19. Chiocca EA (1998). Experimental, and Clinical Gene Therapies for Brain Tumors. In Gene Therapy for Neurological Disorders and Brain Tumors. EA Chiocca and XO Breakefield, Eds. Humana Press, Totowa, NJ. pp 191-203.
20. Gomez-Manzano C, Fueyo J, Kyritsis AP, and Yung WKF (1998). Tumor Suppressor Gene Therapy for Brain Tumors. In Gene Therapy for Neurological Disorders and Brain Tumors. EA Chiocca and XO Breakefield, Eds. Humana Press, Totowa, NJ. pp 205-229.
21. Sampson JH, Bigner DD, and Dranoff G. (1998). Cytokine-Based Gene Therapy for Brain Tumors. In Gene Therapy for Neurological Disorders and Brain Tumors. EA Chiocca and XO Breakefield, Eds. Humana Press, Totowa, NJ. pp 231-294.
22. Tjuvajev JG, Stockhammer G, Desai R, Uehara H, Watanabe K, Gansbacher B, and Blasberg RG (1995). Imaging the expression of transfected genes in vivo. Cancer Res 55, 6126-6132.
23. Tjuvajev JG, Finn R, Watanabe K, Joshi R, Oku T, Kennedy J, Beattie B, Koutcher J, Larson S, and Blasberg RG (1996). Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res 56, 4087-4095.
24. Tjuvajev JG, Avril N, Oku T, Sasajima T, Miyagava T, Joshi R, Safer M, Beattie B, DiResta G, Daghighian F, Augensen F, Koutcher J, Finn R, Zweit J, Humm J, Larson SM, and Blasberg R (1998). Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res 58, 4333-4341.
25. Gambhir SS, Barrio JR, Wu L, Iyer M, Namavari M, Satyamurthy N, Bauer E, Parrish C, MacLaren DC, Borghei AR, Green LA, Sharfstein S, Berk AJ, Cherry SR, Phelps ME, and Herschman HR (1998). Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J Nucl Med 39, 2003-2011.
26. Rogers BE, Rosenfeld ME, Khazaeli MB, Mikheeva G, Stackhouse MA, Liu T, Curiel DT, and Buchsbaum DJ (1997). Localization of iodine-125-mlP-Des-Met14-bombesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer. J Nucl Med 38, 1221-1219.
27. Rosenfeld ME, Rogers BE, Khazaeli MB, Mikheeva G, Raben D, Mayo MS, Curiel DT, and Buchsbaum DJ (1997). Adenoviral-mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo. Clin Cancer Res 3, 1187-1194.
28. Bogdanov A, and Weissleder R (1998). The development of in vivo imaging systems to study gene expression. Tibtech 16, 5-10.
29. Tavitian B, Terrazzino S, Kühnast B, Marzabal S, Stettler O, Dolle F, Deverre JR, Jobert A, Hinnen F, Bendriem B, Crouzel C, and DiGiamberarrdino L (1998). In vivo imaging of oligonucleotides with positron emission tomography. Nat Med 4, 467-471.
30. Chattas IR, Sanes JR, and Majors JE (1991). The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol Cell Biol 11, 5848-5859.
31. Pelletier J, and Sonenberg N (1988). Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 334, 320-325.
32. Jackson RJ, and Kaminski A (1995). Internal initiation of translation in eukaryotes: The picornavirus paradigm and beyond. RNA 1, 985-1000.
33. Jang SK, Davies MV, Kaufman RJ, and Wimmer E (1989). Initiation of protein synthesis by internal entry of ribosomes into the 5′ nontranslated region of encephalomyocarditis virus RNA in vivo. J Virol 63, 1651-1660.
34. Sachs AB, Sarnow P, and Hentze MW (1997). Starting at the beginning, middle, and end: Translation initiation in eukaryotes. Cell 89, 831-838.
35. Tjuvajev JG, Joshi R, Lindsley L, Balatoni J, Finn R, Larson SM, Sadelain M, and Blasberg RG (1998). Noninvasive imaging of HSV1-tk marker gene with FIAU for monitoring transfer and expression of other therapeutic genes by multi-gene delivery vectors. Proc. 45th Annual Meeting of the Society of Nuclear Medicine, Toronto, Ontario, Canada, June 7-11. J Nucl Med 39 [Suppl], 130.
36. Loimas S, Wahlfors J, and Janne J (1998). Herpes simplex virus thymidine kinase-green fluorescent protein fusion gene: new tool for gene transfer studies and gene therapy. Biotechniques 24, 614-618.
37. Shawlot W, Deng JM, Fohn LE, and Behringer RR (1998). Restricted beta-galactosidase expression of a hygromycin-lacZ gene targeted to the beta-actin locus and embryonic lethality of beta-actin mutant mice. Transgenic Res 7, 95-103.
38. Weizsaecker M, Deen DF, Rosenblum ML, Hoshino T, Gutin PH, and Barker M (1981). The 9L rat brain tumor: Description and application of an animal model. J Neurol 224, 183-192.
39. Riviere I, Brose K, and Mulligan RC (1995). Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 92, 6733.
40. Riviere I, and Sadelain M (1997). Methods for the Construction of Retroviral Vectors and Generation of High Titer Producers. In Gene Therapy Protocols: Methods in Molecular Biology. P Robbins, Ed, Humana Press, Totowa, NJ, pp 59-78.
41. Barba D, Hardin J, Sadelain M, and Gage FH (1994). Development of anti-tumor immunity following thymidine kinase mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 91, 4348-4352.
42. Ory DS, Neugeboren BA, and Mulligan RC (1996). A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA 93, 11400-11406.
43. Gallardo HF, Tan C, and Sadelain M (1997). Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood 90, 952-957.
44. Johnston KM, Jacoby D, Pechan PA, Fraefel C, Borghesani P, Schuback D, Dunn RJ, Smith FI, and Breakefield XO (1997). HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gene Ther 8, 359-370.
45. Roberts LO, Seamons RA, and Belsham GJ (1998). Recognition of picornavirus internal ribosome entry sites within cells; influence of cellular and viral proteins. RNA 4, 520-529.
46. Chalfie M, Tu Y, Euskirchen G, Ward WW, and Prasher DC (1994). Green fluorescent protein as a marker for gene expression. Science 263, 802-805.
47. Marshall J, Molloy R, Moss GWJ, Howe JR, and Hughes TE (1995). The jellyfish green fluorescent protein: A new tool for studying ion channel expression and function. Neuron 14, 211-215.
48. Moriyoshi K, Richards LJ, Akazawa C, O'Leary DDM, and Nakanishi S (1996). Labeling neural cells using adenoviral gene transfer of membrane-targeted GFP. Neuron 16, 255-260.
49. Chishima T, Miyagi Y, Wang X, Yamaoka H, Shimada H, Moossa AR, and Hoffman RM (1997). Cancer invasion and micrometastasis visualized in live tissue by green fluorescent protein expression. Cancer Res 57, 2042-2047.
50. Bennett J, Duan D, Engelhardt JF, and Maguire AM (1997). Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction. Invest Ophthalmol Vis Sci 38, 2857-2863.
51. Aboody-Guterman K, Pechan PA, Rainov NG, Sena-Esteves M, Jacobs A, Snyder EY, Wild P, Schraner E, Tobler K, Breakefield XO, and Fraefel C (1997). Green fluorescent protein as a reporter for retrovirus and helper virus-free HSV-1 amplicon vector-mediated gene transfer into neural cells in culture and in vivo. Neuroreport 8, 3801-3808.
52. Fraefel C, Jacoby DR, Lage C, Hilderbrand H, Chou JY, Alt FW, Breakefield XO, and Majzoub JA (1997). Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Mol Med 3, 813-825.
53. Flotte TR, Beck SE, Chesnut K, Potter M, Poirier A, and Zolotukhin S (1998). A fluorescence video-endoscopy technique for detection of gene transfer and expression. Gene Ther 5, 166-173.
54. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, and Seed B (1998). Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715-725.